Ascend Performance Materials Reports Surgical Mask Is In Development With Acteev™ Technology Shows Efficacy Against SARS-CoV-2 Plus Level III Filtration Properties

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

July 13, 2020

Ascend Performance Materials announced it has submitted to the U.S. Food and Drug Administration a 510(k) premarket notification for clearance to market its Acteev™ technology in a pair of high-efficacy surgical masks to protect against SARS-CoV-2, the cause of COVID-19.

Ascend Performance Materials advises the proposed masks also meet the requirements to qualify as Level III under ASTM F2100-19 standards, as tested by independent laboratories as well as Ascend scientists. Level III is the highest tier for physical barrier and safety properties, according to the common international testing standard.

Dr. Gopal said the combination of superior physical properties and antiviral protection is a breakthrough in medical device technology, as many masks succeed either at antiviral protection or at filtration and barrier effectiveness but not at both.

“Previous technologies rely on the materials within a mask to retain an electrical charge to achieve filtration efficiency,” Dr. Gopal said. “But when antimicrobial agents are added, those materials lose their charge and begin to fail as barriers.”

Acteev masks, however, achieve antiviral effectiveness through active zinc ions embedded within the polymer structure of polyamide 66, a hygroscopic nylon material whose equilibrium moisture keeps the zinc ions active.

“With Acteev, we have cracked the code of balancing top physical performance with antiviral protection,” Dr. Gopal said.

The technology, covered by more than 15 patent families, has been tested in multiple end forms, including knit and woven fabrics; engineered plastics; and nanofiber meltblown, microfiber meltblown and spunbond nonwoven materials.

Ascend submitted its first 510(k) to the FDA last month. That submittal requests clearance to market a Level I surgical mask that is effective against SARS-CoV-2.

Also last month, Ascend launched Acteev Protect™, an antimicrobial line of protection specially formulated to guard against the growth of fungi, bacteria and other microbes to keep textiles and nonwoven fabrics fresher for longer. Acteev Protect, available for sale today in the United States and select other jurisdictions, can be used to make face coverings, filtration devices, and textiles for upholstery and apparel such as activewear.

About Acteev

  • Tests show >99% antiviral, antibacterial, antifungal efficacy
  • EPA-registered zinc ions embedded in the polymer
  • Hygroscopic nylon 6,6 fabric attracts moisture, which activates the zinc ions
  • Not a topical treatment or coating
  • Not dependent on silver, copper
  • Proven efficacy in many end forms:
    • Knit and woven fabrics for consumer textiles, upholstery, uniforms, face masks
    • Nanofiber, meltblown and spunbond nonwovens for filtration
    • Fibers for carpets
    • Engineered plastics for high-touch surfaces

DISCLAIMER: Acteev™ technology has been shown in laboratory tests to destroy SARS-CoV-2, the coronavirus that causes COVID-19, and other pathogens including H1N1, coronavirus 229E and Gram-positive and Gram-negative bacteria such as staphylococcus and E. coli. All data presented on this page comes from testing performed by independent third-party laboratories following the protocols of ISO, ASTM or other international standards organizations. Not all claims are permitted in all jurisdictions, including in the United States. Some device designs currently under review with the U.S. Food and Drug Administration — submission number K201714. Ascend has more than 15 patent families pending on Acteev technology.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.